These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 37423623)

  • 1. Study protocol: the ILANA study - exploring optimal implementation strategies for long-acting antiretroviral therapy to ensure equity in clinical care and policy for women, racially minoritised people and older people living with HIV in the UK - a qualitative multiphase longitudinal study design.
    Farooq HZ; Apea V; Kasadha B; Ullah S; Hilton-Smith G; Haley A; Scherzer J; Hand J; Paparini S; Phillips R; Orkin CM
    BMJ Open; 2023 Jul; 13(7):e070666. PubMed ID: 37423623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
    Chounta V; Overton ET; Mills A; Swindells S; Benn PD; Vanveggel S; van Solingen-Ristea R; Wang Y; Hudson KJ; Shaefer MS; Margolis DA; Smith KY; Spreen WR
    Patient; 2021 Nov; 14(6):849-862. PubMed ID: 34056699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of long-acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations.
    Gutner CA; Hocqueloux L; Jonsson-Oldenbüttel C; Vandekerckhove L; van Welzen BJ; Slama L; Crusells-Canales M; Sierra JO; DeMoor R; Scherzer J; Ait-Khaled M; Bontempo G; Gill M; Patel N; D'Amico R; Hove K; Baugh B; Barnes N; Hadi M; Low EL; Anand SB; Hamilton A; Garges HP; Czarnogorski M
    J Int AIDS Soc; 2024 Jul; 27(7):e26243. PubMed ID: 38978405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine.
    Patel P; Teichner P; Elliot E; Boffito M; Murray M; Polli JW; Baker M; Ford SL; Han K; Russu A; Crauwels H; D'Amico RD; Spreen WR; van Wyk J
    Ther Adv Infect Dis; 2023; 10():20499361231214626. PubMed ID: 38107552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Acting Injectable ART in Practice: A Mixed Methods Implementation Study Assessing the Feasibility of Using LAI ART in High Risk Populations and At Alternative Low Barrier Care Sites.
    Fletcher L; Burrowes S; Sabin LL; McCann N; Khan GK; Ruiz-Mercado G; Johnson S; Kimmel SD; Pierre C; Drainoni ML
    AIDS Patient Care STDS; 2024 May; 38(5):221-229. PubMed ID: 38656905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspectives Among Health Care Providers and People with HIV on the Implementation of Long-Acting Injectable Cabotegravir/Rilpivirine for Antiretroviral Therapy in Florida.
    Fisk-Hoffman RJ; Ranger SS; Gracy A; Gracy H; Manavalan P; Widmeyer M; Leeman RF; Cook RL; Canidate S
    AIDS Patient Care STDS; 2024 Jun; 38(6):275-285. PubMed ID: 38686517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study.
    Grinsztejn B; Torres TS; Hoagland B; Jalil EM; Moreira RI; O'Malley G; Shade SB; Benedetti MR; Moreira J; Simpson K; Pimenta MC; Veloso VG;
    JMIR Public Health Surveill; 2023 Apr; 9():e44961. PubMed ID: 37074775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identifying Implementation Determinants and Strategies for Long-Acting Injectable Cabotegravir-Rilpivirine in People With HIV Who Are Virally Unsuppressed.
    Hickey MD; Grochowski J; Mayorga-Munoz F; Oskarsson J; Imbert E; Spinelli M; Szumowski JD; Appa A; Koester K; Dauria EF; McNulty M; Colasanti J; Havlir DV; Gandhi M; Christopoulos KA
    J Acquir Immune Defic Syndr; 2024 Jul; 96(3):280-289. PubMed ID: 38534179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of a Pharmacist-Led, Long-Acting, Injectable Cabotegravir/Rilpivirine Program for HIV-1 at Health System-Based Clinics in the New York Metropolitan Area.
    Nguyen NM; Kavanagh R; Gozar M; Cabral D; Goetz H; Cha A; McGowan JP; Pao ML
    AIDS Patient Care STDS; 2024 Mar; 38(3):115-122. PubMed ID: 38471090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Effectiveness From the Cabotegravir and Rilpivirine Implementation Study in European Locations Study: Phase 3b Hybrid Type III Implementation Study Integrating Cabotegravir + Rilpivirine Long-Acting Into European Clinical Settings.
    Jonsson-Oldenbüttel C; Ghosn J; van der Valk M; Florence E; Vera F; De Wit S; Rami A; Bonnet F; Hocqueloux L; Hove K; Ait-Khaled M; DeMoor R; Bontempo G; Latham CL; Gutner CA; Iyer S; Gill M; Czarnogorski M; D'Amico R; van Wyk J
    J Acquir Immune Defic Syndr; 2024 Aug; 96(5):472-480. PubMed ID: 38985445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain.
    Moreno S; Rivero A; Ventayol P; Falcó V; Torralba M; Schroeder M; Neches V; Vallejo-Aparicio LA; Mackenzie I; Turner M; Harrison C
    Infect Dis Ther; 2023 Aug; 12(8):2039-2055. PubMed ID: 37452174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy.
    Mills A; Richmond GJ; Newman C; Osiyemi O; Cade J; Brinson C; De Vente J; Margolis DA; Sutton KC; Wilches V; Hatch S; Roberts J; McCoig C; Garris C; Vandermeulen K; Spreen WR
    AIDS; 2022 Feb; 36(2):195-203. PubMed ID: 34652287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
    Rizzardini G; Overton ET; Orkin C; Swindells S; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Girard PM; Oka S; Andrade-Villanueva JF; Richmond GJ; Baumgarten A; Masiá M; Latiff G; Griffith S; Harrington CM; Hudson KJ; St Clair M; Talarico CL; Patel P; Cutrell A; Van Eygen V; D'Amico R; Mrus JM; Wu S; Ford SL; Chow K; Roberts J; Wills A; Walters N; Vanveggel S; Van Solingen-Ristea R; Crauwels H; Smith KY; Spreen WR; Margolis DA
    J Acquir Immune Defic Syndr; 2020 Dec; 85(4):498-506. PubMed ID: 33136751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving Adherence to the Target Window for Cabotegravir + Rilpivirine Long-Acting Injections Through the CHORUS™ App and Web Portal: A Cluster Randomized Trial.
    Wohlfeiler MB; Brunet L; Cochran Q; Fusco JS; Hsu RK; Fusco GP
    J Int Assoc Provid AIDS Care; 2024; 23():23259582241245223. PubMed ID: 38613372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study.
    Garris CP; Czarnogorski M; Dalessandro M; D'Amico R; Nwafor T; Williams W; Merrill D; Wang Y; Stassek L; Wohlfeiler MB; Sinclair GI; Mena LA; Thedinger B; Flamm JA; Benson P; Spreen WR
    J Int AIDS Soc; 2022 Sep; 25(9):e26006. PubMed ID: 36097674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials.
    Patel P; Ford SL; Baker M; Meyer C; Garside L; D'Amico R; Van Solingen-Ristea R; Crauwels H; Polli JW; Seal C; Yagüe Muñoz I; Thiagarajah S; Birmingham E; Spreen WR; Baugh B; van Wyk J; Vannappagari V
    HIV Med; 2023 May; 24(5):568-579. PubMed ID: 36411596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study.
    Parker B; Ward T; Hayward O; Jacob I; Arthurs E; Becker D; Anderson SJ; Chounta V; Van de Velde N
    PLoS One; 2021; 16(2):e0245955. PubMed ID: 33529201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-acting prescriptions and therapy for HIV-1 from market launch to the present in Germany (May 2021 to December 2023).
    Schmidt D; Kollan C; Stoll M
    Front Public Health; 2024; 12():1404255. PubMed ID: 38873299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and Evaluation of Dissolving Microarray Patches for Co-administered and Repeated Intradermal Delivery of Long-acting Rilpivirine and Cabotegravir Nanosuspensions for Paediatric HIV Antiretroviral Therapy.
    Moffatt K; Tekko IA; Vora L; Volpe-Zanutto F; Hutton ARJ; Mistilis J; Jarrahian C; Akhavein N; Weber AD; McCarthy HO; Donnelly RF
    Pharm Res; 2023 Jul; 40(7):1673-1696. PubMed ID: 36224503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
    Overton ET; Richmond G; Rizzardini G; Thalme A; Girard PM; Wong A; Porteiro N; Swindells S; Reynes J; Noe S; Harrington C; Español CM; Acuipil C; Aksar A; Wang Y; Ford SL; Crauwels H; van Eygen V; Van Solingen-Ristea R; Latham CL; Thiagarajah S; D'Amico R; Smith KY; Vandermeulen K; Spreen WR
    Clin Infect Dis; 2023 May; 76(9):1646-1654. PubMed ID: 36660819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.